MX2010006882A - Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica. - Google Patents

Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.

Info

Publication number
MX2010006882A
MX2010006882A MX2010006882A MX2010006882A MX2010006882A MX 2010006882 A MX2010006882 A MX 2010006882A MX 2010006882 A MX2010006882 A MX 2010006882A MX 2010006882 A MX2010006882 A MX 2010006882A MX 2010006882 A MX2010006882 A MX 2010006882A
Authority
MX
Mexico
Prior art keywords
sup
pharmaceutical composition
catechol derivative
compound
lower alkyl
Prior art date
Application number
MX2010006882A
Other languages
English (en)
Inventor
Takehiro Ishikawa
Hiroaki Shiohara
Hitoshi Inoue
Satoko Kobayashi
Masako Yoshida
Yasunori Ueno
Nobuyuki Tanaka
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MX2010006882A publication Critical patent/MX2010006882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe un compuesto representado por la fórmula general (I), que tiene un fuerte efecto inhibidor de COMT, o una sal farmacéuticamente aceptable del mismo. También se describen una composición farmacéutica que contiene el compuesto o una sal farmacológicamente aceptable del mismo, y usos del compuesto, una sal farmacéuticamente aceptable del compuesto y la composición farmacéutica. [En la fórmula (I), R1 y R2 respectivamente representan un hidrógeno, un acilo inferior, un alcoxicarbonilo inferior, o similares; R3 representa un alquilo inferior halogenado, un acilo inferior, un alquilcarbonilo inferior halogenado, un cicloalquilcarbonhlo, un arilcarbonilo opcionalmente substituido, un alcoxicarbonilo inferior o similares; y R4 representa un alquilo inferior, un alquilo inferior halogenado, un cicloalquilo, un alcoxi inferior-alquilo inferior, o similares].
MX2010006882A 2007-12-25 2008-12-22 Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica. MX2010006882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007331896 2007-12-25
PCT/JP2008/073269 WO2009081891A1 (ja) 2007-12-25 2008-12-22 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途

Publications (1)

Publication Number Publication Date
MX2010006882A true MX2010006882A (es) 2010-10-05

Family

ID=40801192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006882A MX2010006882A (es) 2007-12-25 2008-12-22 Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.

Country Status (13)

Country Link
US (1) US7923462B2 (es)
EP (1) EP2246338B1 (es)
JP (1) JP5279728B2 (es)
KR (1) KR101613610B1 (es)
CN (1) CN101965339B (es)
AU (1) AU2008342122B2 (es)
BR (1) BRPI0821327A2 (es)
CA (1) CA2708447C (es)
IL (1) IL206562A (es)
MX (1) MX2010006882A (es)
RU (1) RU2459812C2 (es)
TW (1) TWI415607B (es)
WO (1) WO2009081891A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5433505B2 (ja) * 2009-06-18 2014-03-05 キッセイ薬品工業株式会社 ニトロカテコール誘導体の製造方法およびその製造中間体
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
JP5883590B2 (ja) * 2010-08-06 2016-03-15 キッセイ薬品工業株式会社 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
US9682995B2 (en) 2013-01-30 2017-06-20 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
GB201507340D0 (en) 2015-04-29 2015-06-10 Univ St Andrews Light emitting devices and compounds
US11008282B2 (en) * 2015-12-18 2021-05-18 Caprotec Bioanalytics Gmbh Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
CN106478394A (zh) * 2016-09-29 2017-03-08 贵州大学 一种1‑(2‑羟基‑3‑甲氧苯基)乙酮的制备工艺
US11974572B2 (en) * 2017-03-31 2024-05-07 Sygenta Participations Ag Fungicidal compositions
TW202334101A (zh) * 2017-04-06 2023-09-01 美商富曼西公司 殺真菌之噁二唑
WO2019020501A1 (en) * 2017-07-28 2019-01-31 Basf Se PREPARATION OF SUBSTITUTED 3-ARYL-5-TRIFLUOROMETHYL-1,2,4-OXADIAZOLES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU776031A1 (ru) * 1979-03-01 1982-01-23 Пермский государственный фармацевтический институт N-метилфенацил-5-(3-фенил 1,2,4-оксадиазолил)кетон,про вл ющий антимикробную активность
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
ZA879329B (en) 1986-12-12 1988-06-13 Ciba-Geigy Ag Pesticides
EP0276432A3 (de) * 1986-12-12 1988-10-26 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
ES2624610T3 (es) * 2003-04-11 2017-07-17 Ptc Therapeutics, Inc. Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
AU2006272978B2 (en) * 2005-07-26 2012-06-07 Bial - Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors

Also Published As

Publication number Publication date
BRPI0821327A2 (pt) 2015-06-16
AU2008342122B2 (en) 2012-06-14
EP2246338B1 (en) 2013-11-20
US7923462B2 (en) 2011-04-12
CN101965339B (zh) 2013-08-14
JPWO2009081891A1 (ja) 2011-05-06
EP2246338A1 (en) 2010-11-03
EP2246338A4 (en) 2012-03-21
IL206562A (en) 2014-08-31
IL206562A0 (en) 2010-12-30
TW200940055A (en) 2009-10-01
TWI415607B (zh) 2013-11-21
RU2010125903A (ru) 2011-12-27
WO2009081891A1 (ja) 2009-07-02
CA2708447A1 (en) 2009-07-02
KR20100099718A (ko) 2010-09-13
JP5279728B2 (ja) 2013-09-04
US20100280083A1 (en) 2010-11-04
CN101965339A (zh) 2011-02-02
AU2008342122A1 (en) 2009-07-02
RU2459812C2 (ru) 2012-08-27
CA2708447C (en) 2016-05-10
KR101613610B1 (ko) 2016-04-19

Similar Documents

Publication Publication Date Title
MX2010006882A (es) Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
TW200833675A (en) Nicotinamide derivatives
WO2009016462A3 (en) Substituted bicyclolactam compounds
MX2009004910A (es) Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo.
MX2011011136A (es) Eteres diarilicos.
TNSN08407A1 (en) Organic compounds
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
TW200728307A (en) Novel spirochromanone derivatives
MY140841A (en) Indozolone derivatives as 11b-hsd1 inhibitors
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
WO2007135527A3 (en) Benzimidazolyl compounds
GB0607954D0 (en) Organic compounds
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX2012004089A (es) Inhibidores de hsp90.
MX2009001067A (es) Formas cristalinas de analogos de rapamicina.
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
UA99787C2 (en) Lactams as beta secretase inhibitors
WO2007017728A3 (en) Novel heterocyclic compounds

Legal Events

Date Code Title Description
FG Grant or registration